<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945293</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001018</org_study_id>
    <secondary_id>5R01AG047979</secondary_id>
    <nct_id>NCT02945293</nct_id>
  </id_info>
  <brief_title>Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users</brief_title>
  <acronym>CAAP</acronym>
  <official_title>Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the relationship between heavy alcohol use, pain, and&#xD;
      response to pain medication in older adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants complete a phone screen. If still found eligible, the participant&#xD;
      comes in for 1 screening visit (3 hours long). Cognitive/problem solving tests, computerized&#xD;
      tasks, CPT, questionnaires and functional measures are administered along with a screening&#xD;
      blood lab. If a participant is eligible, he/she comes back for 1 full study day visit (9-10&#xD;
      hours long). A testing battery (similar to the one done during the screening visit) is&#xD;
      completed at baseline and again at three timepoints following medication administration.&#xD;
      Blood draws, vital signs, and pupil measurements are taken throughout the day. A follow-up&#xD;
      phone call is completed within a few days of the full study day visit, during which a&#xD;
      questionnaire is given.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>response to a pain stimulus</measure>
    <time_frame>given during study day</time_frame>
    <description>Exposure to cold water, followed by exposure to warm water</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>medication impact , opioid adjective checklist</measure>
    <time_frame>Study day visit (9-10 hours long)</time_frame>
    <description>adjective questionnaire on the impact of study medication scale of 0 t0 4 on likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional measure of balance modified berg balance test</measure>
    <time_frame>Screening visit (3 hours long) and study day visit (9-10 hours long)</time_frame>
    <description>score on a functional questionnaire (0 - 30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil size</measure>
    <time_frame>Study day visit (9-10 hours long)</time_frame>
    <description>measure of pupil diameter in millimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>verbal memory performance on list learning task</measure>
    <time_frame>Study day visit (9-10 hours long)</time_frame>
    <description>immediate and delayed recall of a list of words (score of 0 - 45)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">128</enrollment>
  <condition>Mild to Heavy Alcohol Consumption</condition>
  <arm_group>
    <arm_group_label>Study Procedures</arm_group_label>
    <description>Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed</description>
    <arm_group_label>Study Procedures</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, blood plasma, isolated DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        community dwelling participants in the greater Puget Sound region (Seattle and Tacoma) who&#xD;
        consume alcohol on a frequent basis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 35 years old or above&#xD;
&#xD;
          -  Mild to moderate pain&#xD;
&#xD;
          -  alcohol consumption&#xD;
&#xD;
          -  willingness to refrain from taking any sort of pain medication 24 hours prior to study&#xD;
             visit as well as refraining from taking sedative-hypnotics, antihistamines,&#xD;
             benzodiazepines, sleep aids, NSAIDs/opioid pain medications, alcohol, marijuana&#xD;
&#xD;
          -  Cigarette smokers must be willing to refrain from smoking during the all day study&#xD;
             visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current regular use of an opioid or medications that involve the opioid receptor&#xD;
             (naltrexone (vivitrol), buprenorphine (subutex), methadone (dolophine)&#xD;
&#xD;
          -  abstains from alcohol&#xD;
&#xD;
          -  unstable angina or CHF; cerebral vascular accident or recurrent TIAs in the prior 6&#xD;
             months, active cancer requiring current treatment, possible or probable dementia or&#xD;
             mild cognitive impairment&#xD;
&#xD;
          -  Diagnosis of schizophrenia or schizoaffective disorder, or anxiety disorder requiring&#xD;
             regular medication&#xD;
&#xD;
          -  History of recreational drug use in the past 1 year, excluding marijuana&#xD;
&#xD;
          -  New or increased dose (within last 6 months) of CNS-active medications that may alter&#xD;
             neurocognitive and/or psychomotor function: MAO inhibitors, neuroleptics,&#xD;
             antidepressants, anticonvulsants, benzodiazepines, sleep aids&#xD;
&#xD;
          -  Medications that may alter oxycodone metabolism: St. John's wort, Dilantin, tegretol,&#xD;
             corticosteroids, rifampin&#xD;
&#xD;
          -  Known hypersensitivity to oxycodone and other opioids;&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique M. Cherrier, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cherrier MM, Amory JK, Ersek M, Risler L, Shen DD. Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults. J Pain. 2009 Oct;10(10):1038-50. doi: 10.1016/j.jpain.2009.03.017. Epub 2009 Sep 2.</citation>
    <PMID>19729346</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Monique Cherrier</investigator_full_name>
    <investigator_title>Associate Professor, School of Medicine: Psychiatry And Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Elderly</keyword>
  <keyword>Aged</keyword>
  <keyword>Opioid</keyword>
  <keyword>Cognition</keyword>
  <keyword>Side-effects</keyword>
  <keyword>Alcohol</keyword>
  <keyword>Alcohol Use Disorder (AUD)</keyword>
  <keyword>Older</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>For data obtained at UofW- a de-identified version can be made available upon request for data obtained at VAPSHCS IRB ISO, and PO do not allow the sharing of data, even de-identified data with other investigators- if VA regulations allow data sharing, then the investigators will be allowed to share data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>upon completion of the study a copy of information will be made available on the open science framework site</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT02945293/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>August 23, 2021</submitted>
    <returned>September 17, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

